Fate Therapeutics, Inc. (FRA:F6T)

Market Cap	261.82M +131.5%
Revenue (ttm)	5.68M -23.4%
Net Income	-110.28M
EPS	-0.92
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	2.106
Previous Close	2.030
Day's Range	2.106 - 2.106
52-Week Range	0.790 - 2.666
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 161
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: F6T

Financial Performance

In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error